Activation of the aryl hydrocarbon receptor AhR Promotes retinoic acid-induced differentiation of myeloblastic leukemia cells by restricting expression of the stem cell transcription factor Oct4.
Retinoic acid (RA) is used to treat leukemia and other cancers through its ability to promote cancer cell differentiation. Strategies to enhance the anticancer effects of RA could deepen and broaden its beneficial therapeutic applications. In this study, we describe a receptor cross-talk system that addresses this issue. RA effects are mediated by RAR/RXR receptors that we show are modified by interactions with the aryl hydrocarbon receptor (AhR), a protein functioning both as a transcription factor and a ligand-dependent adaptor in an ubiquitin ligase complex. RAR/RXR and AhR pathways cross-talk at the levels of ligand-receptor and also receptor-promoter interactions. Here, we assessed the role of AhR during RA-induced differentiation and a hypothesized convergence at Oct4, a transcription factor believed to maintain stem cell characteristics. RA upregulated AhR and downregulated Oct4 during differentiation of HL-60 promyelocytic leukemia cells. AhR overexpression in stable transfectants downregulated Oct4 and also decreased ALDH1 activity, another stem cell-associated factor, enhancing RA-induced differentiation as indicated by cell differentiation markers associated with early (CD38 and CD11b) and late (neutrophilic respiratory burst) responses. AhR overexpression also increased levels of activated Raf1, which is known to help propel RA-induced differentiation. RNA interference-mediated knockdown of Oct4 enhanced RA-induced differentiation and G(0) cell-cycle arrest relative to parental cells. Consistent with the hypothesized importance of Oct4 downregulation for differentiation, parental cells rendered resistant to RA by biweekly high RA exposure displayed elevated Oct4 levels that failed to be downregulated. Together, our results suggested that therapeutic effects of RA-induced leukemia differentiation depend on AhR and its ability to downregulate the stem cell factor Oct4.
Department of Biomedical Sciences, Cornell University, Ithaca, New York 14853, USA.
Rodica P
RP
Bunaciu
Andrew
A
Yen
D051997:ADP-ribosyl Cyclase 1 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology; D015153:Blotting, Western; D039481:CD11b Antigen / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects*; D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism; D005434:Flow Cytometry; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D018922:HL-60 Cells; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D050814:Octamer Transcription Factor-3 / Q000235:genetics / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D034622:RNA Interference; D018336:Receptors, Aryl Hydrocarbon / Q000235:genetics / Q000378:metabolism*; D013234:Stem Cells / Q000378:metabolism; D014212:Tretinoin / Q000494:pharmacology*; D048490:raf Kinases / Q000378:metabolism
D000970:Antineoplastic Agents; D039481:CD11b Antigen; D050814:Octamer Transcription Factor-3; C494173:POU5F1 protein, human; D018336:Receptors, Aryl Hydrocarbon; D014212:Tretinoin; D048490:raf Kinases; D051997:ADP-ribosyl Cyclase 1
Cancer Res. 2007 Aug 15;67(16):7765-72
17699781
J Biol Chem. 1991 Sep 5;266(25):16813-7
1653248
Blood. 2004 Sep 15;104(6):1648-55
15178579
Cancer Res. 2010 Jan 1;70(1):212-20
19996281
J Biol Chem. 2009 Nov 27;284(48):33006-18
19805545
J Cell Sci. 2009 Oct 1;122(Pt 19):3502-10
19723802
Mol Endocrinol. 2010 Feb;24(2):359-69
20032195
Am J Pathol. 1972 Mar;66(3):589-92
4551297
Mol Cell Biol. 2004 Mar;24(6):2423-43
14993281
J Immunol. 1990 Apr 1;144(7):2811-5
2319135
J Nutr. 2003 Jan;133(1):277S-281S
12514309
Exp Cell Res. 2009 Aug 1;315(13):2241-8
19298812
J Biol Chem. 2005 Feb 11;280(6):4350-9
15572374
Nature. 2007 Mar 29;446(7135):562-6
17392787
Blood. 1999 Jul 1;94(1):251-9
10381520
Mol Cell Biol. 1995 Aug;15(8):4194-207
7623814
Cancer Res. 1982 Nov;42(11):4701-5
6957260
Nature. 2009 Oct 1;461(7264):649-3
19718018
Curr Drug Metab. 2001 Jun;2(2):149-64
11469723
Carcinogenesis. 2000 Jul;21(7):1271-9
10874003
Cancer Res. 1998 Jul 15;58(14):3163-72
9679985
Zoolog Sci. 2004 May;21(5):541-51
15170058
Eur J Cell Biol. 1994 Oct;65(1):103-13
7889981
J Natl Cancer Inst. 2007 Nov 7;99(21):1603-12
17971525
Cell Stem Cell. 2007 Nov;1(5):555-67
18371393
Mol Pharmacol. 1992 Oct;42(4):603-12
1331752
Nature. 2003 May 29;423(6939):545-50
12774124
In Vitro Cell Dev Biol Anim. 1999 Oct;35(9):527-32
10548434
Genes Cells. 1997 Oct;2(10):645-54
9427285
J Biol Chem. 2008 Feb 15;283(7):4375-86
18006504
Mol Cell Biol. 1998 Dec;18(12):7487-98
9819434
Biochem Biophys Res Commun. 2008 Jun 13;370(4):541-6
18358233
Eur J Biochem. 1995 Jul 15;231(2):337-43
7635145
Biochem Pharmacol. 2009 Feb 15;77(4):474-84
18838062
Trends Biochem Sci. 2009 Oct;34(10):491-9
19733480
Hepatol Res. 2007 Sep;37 Suppl 2:S299-302
17877499
Mol Cell Biol. 1994 Feb;14(2):1026-38
8289783
J Pharmacol Exp Ther. 2005 Jan;312(1):339-45
15470086
Cell. 2007 Nov 30;131(5):861-72
18035408
Mol Cell Biol. 1994 Feb;14(2):1122-36
8289793
Cancer Res. 2006 Sep 15;66(18):9083-9
16982750
Exp Cell Res. 2008 Oct 1;314(16):2999-3006
18692045
J Immunol. 1997 Jul 1;159(1):193-205
9200455
Science. 2007 Dec 21;318(5858):1917-20
18029452
Cold Spring Harb Symp Quant Biol. 2008;73:195-202
19478325